Dr.
The company also announces the retirement of
Dr.
The company anticipates announcing a Head of
Furthermore, the Board of Directors of Galapagos appointed two new members to the Executive Committee:
- Ms. Annelies Missotten, Chief Human Resources Officer
- Annelies joined Galapagos early 2018 from GSK, where she was HR Business Leader of Global Vaccines Commercial & Global Vaccines Strategic Partnerships
- Ms.
Valeria Cnossen , General Counsel, also responsible for Compliance & Ethics, the Corporate Secretary Office and Intellectual Property- Valeria joined Galapagos in
August 2022 . She previously was General Counsel of theConsumer Health Group of Johnson & Johnson and held leadership roles in thePharmaceuticals Group andMedical Devices Group of Johnson & Johnson
- Valeria joined Galapagos in
“I am very pleased that our Executive Committee is strengthened with key strategic positions to help drive future growth. Annelies and Valeria bring a wealth of expertise and will be instrumental in setting and executing on our human capital strategy and our corporate governance,” commented Dr.
About Galapagos
Galapagos is a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines. We are committed to improving patients’ lives worldwide by targeting diseases with high unmet needs. Our R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Our portfolio comprises discovery through to Phase 4 programs in immunology, oncology, and other indications. Our first medicine for rheumatoid arthritis and ulcerative colitis is available in
Except for filgotinib’s approval for the treatment of moderately to severely rheumatoid arthritis and ulcerative colitis by the relevant regulatory authorities in the
Contact
Investors:
Head of Investor Relations
+1 781 296 1143
Director Investor Relations
+32 495 58 46 63
ir@glpg.com
Media:
Head of Corporate Communication
+32 479 490 603
media@glpg.com
Forward-looking statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the announced leadership transition and Executive Committee appointments, benefits the company expects to realize from new additions to its Executive Committee, its ability to accelerate its development activities and its strategic direction model, and other statements contained in this press release that are not historical facts and statements identified by words such as “expects,” “anticipates,” “intends,” “vision,” “aims”, and “plans,” or words of similar meaning. These forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those referred to in the forward-looking statements and, therefore, the reader should not place undue reliance on them. These risks, uncertainties and other factors include, without limitation, the risk that we may not be able to realize the expected benefits from our planned leadership transition, that our leadership transition may be disruptive to our business operations, and those risks and uncertainties identified in our Annual Report on Form 20-F for the year ended 31
1 Acting via
Attachment
- Galapagos announces changes to Executive Committee
Source:
2022 GlobeNewswire, Inc., source